Content reviewed by clinical research staff
Evidence graded using the PeptideScholar A-D system.
Tesofensine is a triple monoamine reuptake inhibitor (noradrenaline, dopamine, serotonin) originally developed for Parkinson's and Alzheimer's diseases. During clinical trials, significant weight loss was observed as a side effect, leading to its repurposing for obesity. A Phase 2 randomized controlled trial published in The Lancet demonstrated dose-dependent weight loss superior to currently approved obesity medications. Note: tesofensine is a small molecule drug — NOT a peptide — but it is commonly discussed in peptide and research chemical communities due to its metabolic effects.
Tesofensine inhibits the presynaptic reuptake of noradrenaline (NET), dopamine (DAT), and serotonin (SERT), increasing synaptic concentrations of all three neurotransmitters. This suppresses appetite via hypothalamic signaling, increases energy expenditure through sympathetic nervous system activation, and may enhance fat oxidation. The net effect is reduced caloric intake, increased satiety, and elevated metabolic rate.
This content is for informational purposes only and does not constitute medical advice.
The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.
Tesofensine is not FDA-approved. Always consult a licensed healthcare provider before considering any peptide.
Use the Peptide FinderUse the guided tool to narrow the safest next step.
Lancet, 2008
Landmark Phase 2 RCT: tesofensine produced dose-dependent weight loss of 4.5–10.6% vs 2.0% for placebo at 24 weeks, exceeding the efficacy of then-approved obesity drugs
Lancet, 2009
Lancet editorial discussing tesofensine trial results, noting efficacy but raising concerns about cardiovascular safety at higher doses
Obesity (Silver Spring), 2012
Tesofensine significantly reduced appetite, hunger, and prospective food consumption while increasing satiety in obese subjects
Eur J Endocrinol, 2022
Phase 2 trial of tesofensine + metoprolol (Tesomet) in hypothalamic obesity, showing significant weight loss in a difficult-to-treat population
The Peptide Protocols Handbook
Evidence-based reference guide covering mechanisms, research, and clinical applications.
View on AmazonThird-Party Peptide Testing
Independent lab analysis to verify peptide purity and authenticity.
Learn MoreLinks may be affiliate links. See our disclosure.
Books covering peptide science, longevity research, and biohacking frameworks.
The Peptide Protocols
Comprehensive reference for peptide mechanisms, dosing research, and clinical applications.
Boundless by Ben Greenfield
Covers peptides, nootropics, hormones, and longevity strategies in an optimization framework.
Lifespan by David Sinclair
Evidence-based deep-dive into aging science, directly relevant to longevity peptide research.
The Longevity Paradox
Gut-centric aging research with diet and supplementation protocols for extending healthspan.
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.